<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on August 6, 2021</div>
      <div style="text-align: right; font-weight: bold;">Registration No. 333&#8209;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
      <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
      <div style="text-align: center; font-weight: bold;">UNDER</div>
      <div style="text-align: center; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">AMRYT PHARMA PLC</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z9ecca240a1a94ba88ab87a1eac21ea06" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 33.35%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">England and Wales</div>
              <div style="text-align: center;">(State or other jurisdiction of</div>
              <div style="text-align: center;">incorporation or organization)</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
              <div style="text-align: center; font-weight: bold;">Dept 920a 196 High Road, Wood Green,</div>
              <div style="text-align: center; font-weight: bold;">London, United Kingdom, N22 8HH</div>
              <div style="text-align: center; font-weight: bold;">Tel: +44 (0)20 3026 7257</div>
            </td>
            <td style="width: 33.32%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Not Applicable</div>
              <div style="text-align: center;">(I.R.S. Employer</div>
              <div style="text-align: center;">Identification No.)</div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">(Address of Principal Executive Offices,</div>
      <div style="text-align: center;">including Zip Code)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Chiasma, Inc. 2008 Stock Incentive Plan</div>
      <div style="text-align: center; font-weight: bold;">Chiasma, Inc. 2015 Stock Option and Incentive Plan</div>
      <div style="text-align: center; font-weight: bold;">Inducement Stock Option Award (April 22, 2020)</div>
      <div style="text-align: center;">(Full title of the plans)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Puglisi &amp; Associates</div>
      <div style="text-align: center; font-weight: bold;">850 Library Avenue, Suite 204</div>
      <div style="text-align: center; font-weight: bold;">Newark, Delaware 19711</div>
      <div style="text-align: center;">(Name and address of agent for service)</div>
      <div style="text-align: center; font-weight: bold;">(302) 738-6680</div>
      <div style="text-align: center;">(Telephone number, including area code, of agent for service)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-style: italic;">With a copy to..</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zc0c28b58863e4da1874288b8b0d8e053" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Boris Dolgonos</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Gibson, Dunn &amp; Crutcher LLP</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">200 Park Avenue</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">New York, NY 10166</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Tel: (212) 351-4000</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Christopher Haynes</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Gibson, Dunn &amp; Crutcher UK LLP</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Telephone House 2-4</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Temple Avenue</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">London, EC4Y 0HB</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">United Kingdom</div>
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Tel: +44 (0) 20-7071 4000</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.&#160; See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
        filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze22f767970ed45cab5231fbef16f8fc9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 29.6%; vertical-align: top;">
              <div>Large accelerated filer</div>
            </td>
            <td style="width: 23.1%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
            <td style="width: 30.8%; vertical-align: top;">
              <div>Accelerated filer</div>
            </td>
            <td style="width: 16.5%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.6%; vertical-align: top;">
              <div>Non-accelerated filer</div>
            </td>
            <td style="width: 23.1%; vertical-align: top;">
              <div>&#9746;</div>
            </td>
            <td style="width: 30.8%; vertical-align: top;">
              <div>Smaller reporting company</div>
            </td>
            <td style="width: 16.5%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.6%; vertical-align: top;">&#160;</td>
            <td style="width: 23.1%; vertical-align: top;">&#160;</td>
            <td style="width: 30.8%; vertical-align: top;">
              <div>Emerging growth company</div>
            </td>
            <td style="width: 16.5%; vertical-align: top;">
              <div>&#9746;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
          transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> &#9744;</font></div>
      <div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </font></div>
      <div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z7a76c45e13f94c88b45cebb196327a74" class="cfttable">

          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); width: 56%;">
              <div style="text-align: center; text-indent: -16.2pt; margin-left: 16.2pt; font-weight: bold;">Title Of Securities</div>
              <div style="text-align: center; text-indent: -16.2pt; margin-left: 16.2pt; font-weight: bold;">To Be Registered</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); width: 9%;">
              <div style="text-align: center; font-weight: bold;">Amount</div>
              <div style="text-align: center; font-weight: bold;">To Be</div>
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; font-weight: bold;">Registered</font><font style="font-family: 'Times New Roman';"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></font></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); width: 9%;">
              <div style="text-align: center; font-weight: bold;">Proposed</div>
              <div style="text-align: center; font-weight: bold;">Maximum</div>
              <div style="text-align: center; font-weight: bold;">Offering Price</div>
              <div style="text-align: center; font-weight: bold;">Per Share</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); width: 9%;">
              <div style="text-align: center; font-weight: bold;">Proposed</div>
              <div style="text-align: center; font-weight: bold;">Maximum</div>
              <div style="text-align: center; font-weight: bold;">Aggregate Offering</div>
              <div style="text-align: center; font-weight: bold;">Price</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); width: 9%;">
              <div style="text-align: center; font-weight: bold;">Amount Of</div>
              <div style="text-align: center; font-weight: bold;">Registration Fee</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 56%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Ordinary shares, nominal value &#163;0.06 per share (&#8220;ordinary shares&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> issuable as stock options pursuant to the Chiasma, Inc. 2008 Stock Incentive Plan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div style="text-align: center;">3,269,765</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif;">$2.68<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
                <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup> </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 12pt;"><font style="font-size: 10pt;">$8,762,970<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></font> <br>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: center; width: 9%;">
              <div style="font-family: 'Times New Roman',Times,serif;">$956.04</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 56%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -9pt; margin-left: 9pt;">Ordinary shares, issuable as stock options pursuant to the Chiasma, Inc. 2015 Stock Option and Incentive Plan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="text-align: center;">14,027,895</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif;">$2.54<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup> </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif; font-size: 12pt;"><font style="font-size: 10pt;">$35,630,853<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></font> <br>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman',Times,serif;">$3,887.33</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 56%;">
              <div style="text-indent: -9pt; margin-left: 9pt;">Ordinary shares issuable as stock options pursuant to the inducement stock option award entered into on April 22, 2020<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: center; width: 9%;"> 841.500<br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div>
                <div style="font-family: 'Times New Roman',Times,serif;">$2.24<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup> </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div>
                <div>$1,884,960<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(<font style="font-family: 'Times New Roman',Times,serif;">4</font>)</sup> </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); width: 9%;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman',Times,serif;">$205.65</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 56%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -9pt; margin-left: 9pt;">Ordinary shares, issuable in respect of restricted stock units pursuant to the Chiasma, Inc. 2015 Stock Option and Incentive Plan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="text-align: center;">202,145</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="text-align: center;">$2.03<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup> <br>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">$410,354<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup> </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">$44.77</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 56%; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -16.2pt; margin-left: 16.2pt;">Total:</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">18,341,305</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div>&#8211;&#8211;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman',Times,serif;">$46,689,137</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-right: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman',Times,serif;">$5,093.79</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6ae2932d85be42bc9627a780318cd884" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">(1)</td>
            <td style="width: auto; vertical-align: top;">
              <div>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also relates to such indeterminable number of additional Ordinary Shares as may be issuable pursuant to stock splits, stock dividends or
                similar transactions.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z79cf4e48a75e4e1a8411f1dd15ad79e2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">(2)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The ordinary shares may be represented by the Registrant&#8217;s American Depositary Shares (&#8220;ADS&#8221;), each of which represents five ordinary shares.&#160; The ADSs have been registered under a registration statement on Form F-6 (registration number
                333-233844), filed with the Commission on September 19, 2019, as amended by Post-Effective Amendment No. 1, filed with the Commission on June 23, 2020.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6d2e893fcc0c4d54a68cadd118960e64" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">(3)</td>
            <td style="width: auto; vertical-align: top;">
              <div>Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based upon the weighted average exercise
                price for shares subject to the outstanding stock options granted pursuant to the applicable plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="z11a66189729541f79cf0e8781792ec70" class="DSPFListTable">

              <tr style="vertical-align: top;">
                <td style="vertical-align: top; width: 36pt;">
                  <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(4)</div>
                </td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate
                    offering price are calculated on the basis of the exercise price of the inducement stock option award.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za4fe006679a64343a5ff53a0113075a8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">(5)</td>
            <td style="width: auto; vertical-align: top;">
              <div>Computed pursuant to Rule 457(h) of the Securities Act solely for purposes of determining the registration fee, based upon an assumed price of $10.13 per ADS, which is based upon the average of the high and low prices of the registrant&#8217;s
                common stock on August 4, 2021, as reported on the Nasdaq Global Select Market and reflects an ADS-to-share ratio of 1 to 5.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXPLANATORY NOTE</div>
      <div>&#160;</div>
      <div>On May 4, 2021, Chiasma, Inc., a Delaware corporation (&#8220;Chiasma&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Amryt Pharma plc, a public limited company incorporated under the laws of England and Wales (the
        &#8220;Company&#8221; or the &#8220;Registrant&#8221;), and Acorn Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), pursuant to which, subject to the satisfaction or waiver of the conditions therein, Merger Sub
        will merge with and into Chiasma (the &#8220;Merger&#8221;), with Chiasma surviving as an indirect wholly owned subsidiary of the Company.&#160; The Merger was completed on August 5, 2021.&#160; This Registration Statement on Form S-8 is filed by the Company, relating
        to 18,341,305 of its ordinary shares, issuable to eligible employees of the Company pursuant to awards assumed by the Company granted under the Chiasma, Inc. 2008 Stock Option Plan, the Chiasma, Inc. 2015 Stock Option and Incentive Plan and the
        Inducement Stock Option Agreement dated April 22, 2020 (collectively, the &#8220;Plan&#8221;), in accordance with the terms of the Merger Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">PART I</div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
      <div>&#160;</div>
      <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; font-weight: bold;">All information required by Part </font><font style="font-family: 'Times New Roman';">I of Form S-8 to be contained in the
          prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act.</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">PART II</div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
      <div>&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z56885ac720c84fe5a5dab321fb7bc2ee" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="width: 36pt;">&#160;</td>
              <td style="vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-weight: bold;">Item 3.&#160; <br>
                </div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: left; font-weight: bold;">&#160;Incorporation of Documents by Reference.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">The following documents filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) are hereby incorporated by reference in this Registration Statement:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc4799ee654874f05809d9e0c2d5005fe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Registrant&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2020 filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1783010/000114036121015121/brhc10023733_20f.htm">April 30, 2021</a>
                (the &#8220;Annual Report&#8221;) that contains audited financial statements for the Registrant's latest fiscal year for which such statements have been filed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdb76bf065c7e42d18f79fc04b133b9a6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div>All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), since the end of the fiscal year covered by the registration statement referred to in
                (a) above (other than portions of those documents furnished or not otherwise deemed to be filed).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z43e22e8f798c4bdaba2c031fb9478860" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(c)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The description of the Registrant&#8217;s ordinary shares and American Depositary Shares contained in the Registrant&#8217;s registration statement on Form F-1 filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1783010/000114036120014573/nt10012315x3_f1.htm">June 23, 2020</a>, as amended and supplemented by Amendment Nos. 1 and 2 on Form F-1/A filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1783010/000114036120015436/nt10012315x6_f1a.htm">July 6, 2020</a> and <a href="https://www.sec.gov/Archives/edgar/data/1783010/000114036120015527/nt10012315x7_f1a.htm">July 7, 2020</a>,
                respectively, as updated by Exhibit 2.7 to the Annual Report, and as subsequently amended or updated.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and, to the extent specifically designated therein, Reports of Foreign Private Issuer on Form 6-K
        furnished by the Registrant to the Commission that are identified in such forms as being incorporated into this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all of the
        securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of filing such documents.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z79b39c52ef744a01902521ce853c35c7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 4.</td>
            <td style="vertical-align: top;">
              <div style="font-weight: bold;">Description of Securities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable</div>
      <div style="text-indent: 36pt;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z91ed1f1cdf564b58907043863fd5a656" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 5.</td>
            <td style="vertical-align: top;">
              <div style="font-weight: bold;">Interests of Named Experts and Counsel.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z42978da520c44f8884c81e12bb042b8d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 6.</td>
            <td style="vertical-align: top;">
              <div style="font-weight: bold;">Indemnification of Directors and Officers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>To the extent permitted by law, pursuant to the Registrant&#8217;s Articles of Association, current and former members of the Registrant&#8217;s board of directors and its current and former officers shall be entitled to, and current and former directors
        and officers of certain affiliated companies may, at the discretion of the Registrant&#8217;s board of directors, be indemnified by the Company against all liabilities, costs, charges and expenses incurred by him or her in the execution and discharge of
        his or her duties to the Registrant and certain affiliated companies, including any liability incurred in defending any proceedings, civil or criminal, relating to the execution and discharge of his or her duties to the Registrant and certain
        affiliated companies.</div>
      <div>&#160;</div>
      <div>However, pursuant to the Companies Act 1985, no such indemnity shall extend to any liability attaching to a director in connection with any negligence, default, breach of duty or breach of trust in relation to the Registrant.&#160; This prohibition
        does not apply to &#8220;qualifying third party indemnities,&#8221; being indemnities provided against liability incurred by a director to a person other than the Registrant or an associated company (as defined in the Companies Act 1985), except that no such
        qualifying third party indemnities can provide indemnification against:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z58648480e8ba4cc4ad8767cc69185f55" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(i)</td>
            <td style="width: auto; vertical-align: top;">
              <div>any fine imposed in any criminal proceedings;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z237a88e4876242378712f01a75fdeca2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(ii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>any sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature howsoever arising;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4ef0d8a9a59b43e185535bac20c2fd56" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(iii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>any liability incurred in defending any criminal proceedings in which he or she is convicted and such conviction has become final;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdee9116caa9b40f099f38b7656476acb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(iv)</td>
            <td style="width: auto; vertical-align: top;">
              <div>any liability incurred in defending any civil proceedings brought by the Registrant or any associated company in which a final judgment has been given against him or her; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2093b3f7936842f488556b6918fa6a65" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(v)</td>
            <td style="width: auto; vertical-align: top;">
              <div>any liability incurred in connection with any application for relief under certain provisions of the Companies Act 1985 in which the court refuses to grant him or her relief and such refusal has become final.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>In addition, the Registrant is not prevented from purchasing and maintaining for a director of the Registrant, or of an associated company, insurance against any such liability.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">Insofar as indemnification of liabilities arising under the Securities Act of 1933 may be permitted to the Registrant&#8217;s board, executive officers, or persons controlling the Registrant pursuant to the foregoing
        provisions, the Registrant has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zeb2071640e9f4c4fb1432bfbdd27bc1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 7.</td>
            <td style="vertical-align: top;">
              <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Not applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9658074894ab42b5bc3a2fcc121659b1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 8.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">The following exhibits are filed as part of this Registration Statement:</div>
      <div style="text-indent: 36pt;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z4288d0963b0c467aa67cf21132e58dae" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="font-weight: bold;">Exhibit</div>
                <div style="font-weight: bold;">Number</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="font-weight: bold;">Description of Document</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1783010/000114036120014573/nt10012315x3_ex3-1.htm">4.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Articles of Association of Amryt Pharma plc, filed as Exhibit 3.1 to the Registrant&#8217;s Registration Statement on Form F-1 filed with the Commission on June 23, 2020 (File No. 333-239395)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1339469/000119312515245518/d892345dex31.htm">4.3*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Chiasma, Inc. 2015 Stock Option and Incentive Plan, filed as Exhibit 3.1 to Chiasma Inc.&#8217;s Amendment No. 1 to Registration Statement on Form S-1/A filed with the Commission on July 6, 2015 (File No. 333-204949)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc10027685_ex5-1.htm">5.1*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Opinion of Opinion of Gibson, Dunn &amp; Crutcher UK LLP, with respect to the legality of the securities being registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc10027685_ex5-1.htm">23.1*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Consent of Opinion of Gibson, Dunn &amp; Crutcher UK LLP (included in the opinion filed as Exhibit 5.1)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc10027685_ex23-2.htm">23.2*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Consent of Grant Thornton with respect to financial statements of Amryt Pharma plc</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#LimitedPowerofAttorney">24.1*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Limited Power of Attorney of the directors of the Registrant (included on the signature pages hereto)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1339469/000119312515223126/d892345dex102.htm">99.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="font-family: 'Times New Roman',Times,serif;">2008 Stock Incentive Plan and forms of agreement thereunder (Incorporated by reference to Exhibit 10.2 to the registrant's Registration Statement on Form S-1, as amended (File No.
                333-204949)).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1339469/000119312521069604/d240348dex992.htm">99.2</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="font-family: 'Times New Roman',Times,serif;">Form of Inducement Stock Option Award (April 22, 2020) (filed as Exhibit 99.2 to Chiasma Inc.'s Registration Statement on Form S-8 filed with the Commission on July 21, 2015.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>* Filed herewith.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zeb7604f40f8c4c66a3dd0bdadf5a8cce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 9.</td>
            <td style="vertical-align: top;">
              <div style="font-weight: bold;">Undertakings.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">&#160;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The undersigned Registrant hereby undertakes:</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-left: 72pt;">(1)&#160;&#160;&#160;&#160; &#160;&#160; to file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this Registration Statement to include any material
        information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the Registration Statement;</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-left: 72pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the
        securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof; and</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-left: 72pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#160;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The undersigned Registrant hereby further undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to
        Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
        time shall be deemed to be the initial <font style="font-style: italic;">bona fide </font>offering thereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#160;(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
        provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.&#160; In the event that a claim for
        indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
        by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
        jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
      <div style="text-indent: 36pt; margin-left: 36pt;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be
        signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, the United Kingdom on August 6, 2021.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze0b4be04ac3b4ad389a211f3975d68bf" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 49.98%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-weight: bold;">Amryt Pharma Plc</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div>(Registrant)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Dr. Joseph A. Wiley</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Dr. Joseph A. Wiley</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Limited Power of Attorney<a name="LimitedPowerofAttorney"><!--Anchor--></a></div>
      <div style="text-align: center;">(Form S-8)</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of Amryt Pharma Plc, a corporation organized under the laws of England and Wales (the &#8220;Company&#8221;), does hereby constitute and
        appoint each of Joseph Wiley and Rory Nealon as his or her true and lawful attorney-in-fact and agent, to do or cause to be done any and all acts and things and to execute any and all instruments and documents which said attorneys-in-fact and
        agents may deem advisable or necessary to enable the Company to comply with the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and any rules, regulations and requirements of the Securities and Exchange Commission in respect thereof, in
        connection with the registration of the securities or deferred compensation obligations of the Company being registered on the Registration Statement on Form S-8 to which this power of attorney is filed as an exhibit (the &#8220;Securities&#8221;), including
        specifically, but without limiting the generality of the foregoing, power and authority to sign, in the name and on behalf of each of the undersigned as a director of the Company, the Registration Statement on Form S-8 to which this power of
        attorney is filed as an exhibit, a Registration Statement under Rule 462(b) of the Securities Act, or another appropriate form in respect of the registration of the Securities, and any and all amendments thereto, including post-effective
        amendments, and any instruments, contracts, documents or other writings of which the originals or copies thereof are to be filed as a part of, or in connection with, any such Registration Statement or any other appropriate form or amendments
        thereto, and to file or cause to be filed the same with the Securities and Exchange Commission, and to effect any and all applications and other instruments in the name and on behalf of each of the undersigned which said attorneys-in-fact and
        agents deem advisable in order to qualify or register the Securities under the securities laws of any of the several States or other jurisdictions; and each of the undersigned does hereby ratify all that said attorneys-in-fact and agents shall do
        or cause to be done by virtue thereof.&#160; Each attorney-in-fact and agent is hereby granted full power of substitution and revocation with respect hereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">IN WITNESS WHEREOF, each of the undersigned has executed this Limited Power of Attorney as of and on the dates indicated below.&#160; Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration
        Statement has been signed below by the following persons in the capacities and on the dates indicated.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z44101f17ea594f6da0f07d13743e2952" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Signatures</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td style="width: 15%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Dr. Joseph A. Wiley</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Chief Executive Officer</div>
              <div style="text-align: center;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Dr. Joseph A. Wiley</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Rory P. Nealon</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Chief Financial Officer and Chief Operating Officer</div>
              <div style="text-align: center;">(Principal Financial Accounting Officer)</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Rory P. Nealon</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Raymond T. Stafford</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Chairman of the Board</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Raymond T. Stafford</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze3cc433f78264d9ab4fe62ef417740ad" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Donald K. Stern</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Donald K. Stern</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Dr. Alain H. Munoz</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Dr. Alain H. Munoz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Dr. Patrick V.J.J. Vink</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Dr. Patrick V.J.J. Vink</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Stephen T. Willis</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Stephen T. Wills</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ George P. Hampton, Jr.</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>George P. Hampton, Jr.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Raj Kannan</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Raj Kannan</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: middle;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Roni Mamluk</div>
            </td>
            <td style="width: 45%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 15%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">August 6, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div>Roni Mamluk</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">Signature of Authorized U.S. Representative of Registrant</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of Amryt Pharma Plc, has signed this Registration Statement on August 6,
        2021.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zdc52a2a92e014e17a26c178eb8a2aea6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid black;" colspan="2">
              <div>/s/ Donald Puglisi</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">
              <div>Donald Puglisi</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">
              <div>Authorized Representative in the United States</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div style="text-align: center;"> <br>
      <font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "brhc10027685_s8.htm", "description": "S-8", "secsgml_size_bytes": 88007}]
{"company-data": {"conformed-name": "Amryt Pharma plc", "cik": "0001783010", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "X0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-258557", "film-number": "211152474"}, "business-address": {"street1": "DEPT 920A, 196 HIGH ROAD", "street2": "WOOD GREEN", "city": "LONDON", "state": "X0", "zip": "N22 8HH", "phone": "353-1-518-0200"}, "mail-address": {"street1": "90 HARCOURT STREET", "city": "DUBLIN", "state": "L2", "zip": "D02 CR98"}, "former-company": {"former-conformed-name": "Amryt Pharma Holdings Ltd", "date-changed": "20190719"}}
As filed with the Securities and Exchange Commission on August 6, 2021
Registration No. 333‑
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
AMRYT PHARMA PLC
England and Wales
(State or other jurisdiction of
incorporation or organization)
(Exact name of registrant as specified in its charter)
Dept 920a 196 High Road, Wood Green,
London, United Kingdom, N22 8HH
Tel: +44 (0)20 3026 7257
Not Applicable
(I.R.S. Employer
Identification No.)
(Address of Principal Executive Offices,
including Zip Code)
Chiasma, Inc. 2008 Stock Incentive Plan
Chiasma, Inc. 2015 Stock Option and Incentive Plan
Inducement Stock Option Award (April 22, 2020)
(Full title of the plans)
Puglisi & Associates
850 Library Avenue, Suite 204
Newark, Delaware 19711
(Name and address of agent for service)
(302) 738-6680
(Telephone number, including area code, of agent for service)
With a copy to..
Boris Dolgonos
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, NY 10166
Tel: (212) 351-4000
Christopher Haynes
Gibson, Dunn & Crutcher UK LLP
Telephone House 2-4
Temple Avenue
London, EC4Y 0HB
United Kingdom
Tel: +44 (0) 20-7071 4000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of "large accelerated filer," "accelerated
        filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☐
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
          transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title Of Securities
To Be Registered
Amount
To Be
Registered
(1)
Proposed
Maximum
Offering Price
Per Share
Proposed
Maximum
Aggregate Offering
Price
Amount Of
Registration Fee
Ordinary shares, nominal value £0.06 per share ("ordinary shares")
(2)
issuable as stock options pursuant to the Chiasma, Inc. 2008 Stock Incentive Plan
(3)
3,269,765
$2.68
(3)
$8,762,970
(3)
$956.04
Ordinary shares, issuable as stock options pursuant to the Chiasma, Inc. 2015 Stock Option and Incentive Plan
(3)
14,027,895
$2.54
(3)
$35,630,853
(3)
$3,887.33
Ordinary shares issuable as stock options pursuant to the inducement stock option award entered into on April 22, 2020
(4)
841.500
$2.24
(4)
$1,884,960
(
4
)
$205.65
Ordinary shares, issuable in respect of restricted stock units pursuant to the Chiasma, Inc. 2015 Stock Option and Incentive Plan
(5)
202,145
$2.03
(5)
$410,354
(5)
$44.77
Total:
18,341,305
––
$46,689,137
$5,093.79
(1)
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement also relates to such indeterminable number of additional Ordinary Shares as may be issuable pursuant to stock splits, stock dividends or
                similar transactions.
(2)
The ordinary shares may be represented by the Registrant's American Depositary Shares ("ADS"), each of which represents five ordinary shares.  The ADSs have been registered under a registration statement on Form F-6 (registration number
                333-233844), filed with the Commission on September 19, 2019, as amended by Post-Effective Amendment No. 1, filed with the Commission on June 23, 2020.
(3)
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based upon the weighted average exercise
                price for shares subject to the outstanding stock options granted pursuant to the applicable plan.
(4)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate
                    offering price are calculated on the basis of the exercise price of the inducement stock option award.
(5)
Computed pursuant to Rule 457(h) of the Securities Act solely for purposes of determining the registration fee, based upon an assumed price of $10.13 per ADS, which is based upon the average of the high and low prices of the registrant's
                common stock on August 4, 2021, as reported on the Nasdaq Global Select Market and reflects an ADS-to-share ratio of 1 to 5.
2
EXPLANATORY NOTE
On May 4, 2021, Chiasma, Inc., a Delaware corporation ("Chiasma"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Amryt Pharma plc, a public limited company incorporated under the laws of England and Wales (the
        "Company" or the "Registrant"), and Acorn Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of the Company ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of the conditions therein, Merger Sub
        will merge with and into Chiasma (the "Merger"), with Chiasma surviving as an indirect wholly owned subsidiary of the Company.  The Merger was completed on August 5, 2021.  This Registration Statement on Form S-8 is filed by the Company, relating
        to 18,341,305 of its ordinary shares, issuable to eligible employees of the Company pursuant to awards assumed by the Company granted under the Chiasma, Inc. 2008 Stock Option Plan, the Chiasma, Inc. 2015 Stock Option and Incentive Plan and the
        Inducement Stock Option Agreement dated April 22, 2020 (collectively, the "Plan"), in accordance with the terms of the Merger Agreement.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
All information required by Part
I of Form S-8 to be contained in the
          prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents filed with the Securities and Exchange Commission (the "Commission") are hereby incorporated by reference in this Registration Statement:
(a)
The Registrant's annual report on Form 20-F for the fiscal year ended December 31, 2020 filed with the Commission on
April 30, 2021
(the "Annual Report") that contains audited financial statements for the Registrant's latest fiscal year for which such statements have been filed.
(b)
All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), since the end of the fiscal year covered by the registration statement referred to in
                (a) above (other than portions of those documents furnished or not otherwise deemed to be filed).
(c)
The description of the Registrant's ordinary shares and American Depositary Shares contained in the Registrant's registration statement on Form F-1 filed with the Commission on
June 23, 2020
, as amended and supplemented by Amendment Nos. 1 and 2 on Form F-1/A filed with the Commission on
July 6, 2020
and
July 7, 2020
,
                respectively, as updated by Exhibit 2.7 to the Annual Report, and as subsequently amended or updated.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and, to the extent specifically designated therein, Reports of Foreign Private Issuer on Form 6-K
        furnished by the Registrant to the Commission that are identified in such forms as being incorporated into this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all of the
        securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of filing such documents.
Item 4.
Description of Securities.
Not applicable
3
Item 5.
Interests of Named Experts and Counsel.
Not applicable
Item 6.
Indemnification of Directors and Officers.
To the extent permitted by law, pursuant to the Registrant's Articles of Association, current and former members of the Registrant's board of directors and its current and former officers shall be entitled to, and current and former directors
        and officers of certain affiliated companies may, at the discretion of the Registrant's board of directors, be indemnified by the Company against all liabilities, costs, charges and expenses incurred by him or her in the execution and discharge of
        his or her duties to the Registrant and certain affiliated companies, including any liability incurred in defending any proceedings, civil or criminal, relating to the execution and discharge of his or her duties to the Registrant and certain
        affiliated companies.
However, pursuant to the Companies Act 1985, no such indemnity shall extend to any liability attaching to a director in connection with any negligence, default, breach of duty or breach of trust in relation to the Registrant.  This prohibition
        does not apply to "qualifying third party indemnities," being indemnities provided against liability incurred by a director to a person other than the Registrant or an associated company (as defined in the Companies Act 1985), except that no such
        qualifying third party indemnities can provide indemnification against:
(i)
any fine imposed in any criminal proceedings;
(ii)
any sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature howsoever arising;
(iii)
any liability incurred in defending any criminal proceedings in which he or she is convicted and such conviction has become final;
(iv)
any liability incurred in defending any civil proceedings brought by the Registrant or any associated company in which a final judgment has been given against him or her; and
(v)
any liability incurred in connection with any application for relief under certain provisions of the Companies Act 1985 in which the court refuses to grant him or her relief and such refusal has become final.
In addition, the Registrant is not prevented from purchasing and maintaining for a director of the Registrant, or of an associated company, insurance against any such liability.
Insofar as indemnification of liabilities arising under the Securities Act of 1933 may be permitted to the Registrant's board, executive officers, or persons controlling the Registrant pursuant to the foregoing
        provisions, the Registrant has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
The following exhibits are filed as part of this Registration Statement:
4
Exhibit
Number
Description of Document
4.1
Articles of Association of Amryt Pharma plc, filed as Exhibit 3.1 to the Registrant's Registration Statement on Form F-1 filed with the Commission on June 23, 2020 (File No. 333-239395)
4.3*
Chiasma, Inc. 2015 Stock Option and Incentive Plan, filed as Exhibit 3.1 to Chiasma Inc.'s Amendment No. 1 to Registration Statement on Form S-1/A filed with the Commission on July 6, 2015 (File No. 333-204949)
5.1*
Opinion of Opinion of Gibson, Dunn & Crutcher UK LLP, with respect to the legality of the securities being registered
23.1*
Consent of Opinion of Gibson, Dunn & Crutcher UK LLP (included in the opinion filed as Exhibit 5.1)
23.2*
Consent of Grant Thornton with respect to financial statements of Amryt Pharma plc
24.1*
Limited Power of Attorney of the directors of the Registrant (included on the signature pages hereto)
99.1
2008 Stock Incentive Plan and forms of agreement thereunder (Incorporated by reference to Exhibit 10.2 to the registrant's Registration Statement on Form S-1, as amended (File No.
                333-204949)).
99.2
Form of Inducement Stock Option Award (April 22, 2020) (filed as Exhibit 99.2 to Chiasma Inc.'s Registration Statement on Form S-8 filed with the Commission on July 21, 2015.
* Filed herewith.
Item 9.
Undertakings.
(a)         The undersigned Registrant hereby undertakes:
(1)        to file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this Registration Statement to include any material
        information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the Registration Statement;
(2)          that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the
        securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof; and
(3)          to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)         The undersigned Registrant hereby further undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to
        Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
        time shall be deemed to be the initial
bona fide
offering thereof.
(c)         Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
        provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for
        indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
        by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
        jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be
        signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, the United Kingdom on August 6, 2021.
Amryt Pharma Plc
(Registrant)
By:
/s/ Dr. Joseph A. Wiley
Dr. Joseph A. Wiley
Chief Executive Officer
Limited Power of Attorney
(Form S-8)
KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of Amryt Pharma Plc, a corporation organized under the laws of England and Wales (the "Company"), does hereby constitute and
        appoint each of Joseph Wiley and Rory Nealon as his or her true and lawful attorney-in-fact and agent, to do or cause to be done any and all acts and things and to execute any and all instruments and documents which said attorneys-in-fact and
        agents may deem advisable or necessary to enable the Company to comply with the Securities Act of 1933, as amended (the "Securities Act"), and any rules, regulations and requirements of the Securities and Exchange Commission in respect thereof, in
        connection with the registration of the securities or deferred compensation obligations of the Company being registered on the Registration Statement on Form S-8 to which this power of attorney is filed as an exhibit (the "Securities"), including
        specifically, but without limiting the generality of the foregoing, power and authority to sign, in the name and on behalf of each of the undersigned as a director of the Company, the Registration Statement on Form S-8 to which this power of
        attorney is filed as an exhibit, a Registration Statement under Rule 462(b) of the Securities Act, or another appropriate form in respect of the registration of the Securities, and any and all amendments thereto, including post-effective
        amendments, and any instruments, contracts, documents or other writings of which the originals or copies thereof are to be filed as a part of, or in connection with, any such Registration Statement or any other appropriate form or amendments
        thereto, and to file or cause to be filed the same with the Securities and Exchange Commission, and to effect any and all applications and other instruments in the name and on behalf of each of the undersigned which said attorneys-in-fact and
        agents deem advisable in order to qualify or register the Securities under the securities laws of any of the several States or other jurisdictions; and each of the undersigned does hereby ratify all that said attorneys-in-fact and agents shall do
        or cause to be done by virtue thereof.  Each attorney-in-fact and agent is hereby granted full power of substitution and revocation with respect hereto.
IN WITNESS WHEREOF, each of the undersigned has executed this Limited Power of Attorney as of and on the dates indicated below.  Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration
        Statement has been signed below by the following persons in the capacities and on the dates indicated.
Signatures
Title
Date
/s/ Dr. Joseph A. Wiley
Chief Executive Officer
(Principal Executive Officer)
August 6, 2021
Dr. Joseph A. Wiley
/s/ Rory P. Nealon
Chief Financial Officer and Chief Operating Officer
(Principal Financial Accounting Officer)
August 6, 2021
Rory P. Nealon
/s/ Raymond T. Stafford
Chairman of the Board
August 6, 2021
Raymond T. Stafford
6
/s/ Donald K. Stern
Director
August 6, 2021
Donald K. Stern
/s/ Dr. Alain H. Munoz
Director
August 6, 2021
Dr. Alain H. Munoz
/s/ Dr. Patrick V.J.J. Vink
Director
August 6, 2021
Dr. Patrick V.J.J. Vink
/s/ Stephen T. Willis
Director
August 6, 2021
Stephen T. Wills
/s/ George P. Hampton, Jr.
Director
August 6, 2021
George P. Hampton, Jr.
/s/ Raj Kannan
Director
August 6, 2021
Raj Kannan
/s/ Roni Mamluk
Director
August 6, 2021
Roni Mamluk
7
Signature of Authorized U.S. Representative of Registrant
Pursuant to the requirements of the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of Amryt Pharma Plc, has signed this Registration Statement on August 6,
        2021.
By:
/s/ Donald Puglisi
Name:
Donald Puglisi
Title:
Authorized Representative in the United States
8